Positive Data Reported for Monoclonal Antibody Treatment

June 23, 2020

Positive Data Reported for Monoclonal Antibody Treatment

Humanigen has reported positive data from the first clinical use of lenzilumab, which is a humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, in 12 COVID-19 patients. Those treated with the drug fully recovered in 5 days. Yourway has been working throughout the pandemic to transport clinical trial materials to patients that need it, despite challenges involving border closure and supply chain disruptions.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

GCSG 2026 US Conference

April 27-29, 2026
San Diego, CA

Schedule a Meeting

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Schedule a Meeting

Media

Articles

Maintaining Temperature Integrity in Direct-to-Patient Clinical Trials

Open chat

Hello! How can I help you?